REGN Financial Facts
Net loss: 264.8MTotal expenses: 857.32M
See Full Income Statement
Other long term liabilities: 135.7M
Accounts receivable - other: 1.33B
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | 7/30/26 | EPS Growth Rate | -15.8% |
|---|---|---|---|
| Average EPS % Beat Rate | +22.2% | Revenue Growth Rate | +3.8% |
| Average % Move 1-Wk after EPS | +2.7% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
7/30/26  |
Q226 | N/A | $10.85 | N/A | N/A | $3.82B | N/A | N/A | N/A | ||
| 4/29/26 | Q126 | $9.47 | $8.97 | +$0.50 | $3.6B | $3.48B | N/A |  | | Details | |
| 1/30/26 | Q425 | $11.44 | $10.52 | +$0.92 | $3.88B | $3.77B | N/A | | | Details | |
| 10/28/25 | Q325 | $11.83 | $9.64 | +$2.19 | $3.75B | $3.59B | N/A | | | Details | |
| 8/1/25 | Q225 | $12.89 | $8.50 | +$4.39 | $3.68B | $3.29B | N/A | | | Details | |
| 4/29/25 | Q125 | $8.22 | $8.48 | -$0.26 | $3.03B | $3.24B | N/A | | | Details | |
| 2/4/25 | Q424 | $12.07 | $11.27 | +$0.80 | $3.79B | $3.76B | N/A | | | Details | |
| 10/31/24 | Q324 | $12.46 | $11.72 | +$0.74 | $3.72B | $3.66B | N/A | | | Details |
